We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Spectrum Settles With Glaxo Over Imitrex

Law360 (November 13, 2006, 12:00 AM EST) -- Specialty drug maker Spectrum Pharmaceuticals Inc. has settled a patent infringement suit with GlaxoSmithKline over the use of the migraine injection treatment Imitrex.

The deal, announced Monday, will allow Spectrum to exclusively distribute generic Imitrex in the United States starting no later than Nov. 6, 2008. Spectrum added that the expected launch date is August of that year, around the time Glaxo’s pediatric exclusivity period begins for sumatriptan, the active ingredient in Imitrex.

“This settlement with GlaxoSmithKline for sumatriptan injection represents another milestone,” said Spectrum’s President...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.